Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | SCN4A | P35499 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 2/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1034046 | 0.89 | GSK3B (0.33) | MEN1KMT2ADYRK1AEPHX2SCN4A | |
| SCHEMBL1034624 | 0.87 | RORA (0.34) | MEN1KMT2ADYRK1AEPHX2SCN4A | |
| SCHEMBL1030697 | 0.85 | PTGER1 (0.34) | DYRK1AEPHX2SCN4ACSNK1DHRH4 | |
| SCHEMBL4655158 | 0.82 | ESR1 (0.43) | MEN1KMT2ADYRK1APPARA | |
| SCHEMBL4655160 | 0.82 | ESR1 (0.43) | MEN1KMT2ADYRK1APPARA | |
| SCHEMBL718341 | 0.81 | MEN1 (0.39) | MEN1KMT2ADYRK1AEPHX2SCN4A | |
| SCHEMBL14016166 | 0.78 | ESR1 (0.40) | MAPT | |
| SCHEMBL1034047 | 0.77 | KIF11 (0.36) | MEN1KMT2ADYRK1AEPHX2SCN4A | |
| SCHEMBL4654027 | 0.75 | MEN1 (0.39) | MEN1KMT2ADYRK1AEPHX2SCN4A | |
| SCHEMBL12095474 | 0.73 | KDM4E (0.40) | MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104672220-A | Activating agent for peroxisome proliferator activated receptor | NIPPON CHEMIPHAR CO | 2015-06-03 | — | — | CN | disclosed |
| CN-102083810-B | Activator of peroxisome proliferator activated receptor | NIPPON CHEMIPHAR CO.,LTD. (JP) | 2014-10-29 | — | — | CN | disclosed |
| US-8648208-B2 | Activating agent for peroxisome proliferator activated receptor | NIPPON CHEMIPHAR CO. LTD. (JP) | 2014-02-11 | — | — | US | disclosed |
| CN-102083810-A | Activator of peroxisome proliferator activated receptor | NIPPON CHEMIPHAR CO | 2011-06-01 | — | — | CN | disclosed |
| US-20110098480-A1 | ACTIVATING AGENT FOR PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR | NIPPON CHEMIPHAR CO. LTD. (JP) | 2011-04-28 | — | — | US | disclosed |
| EP-1740568-B1 | BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES USEFUL FOR THE TREATMENT OF CARDIOVASCULAR DISEASE. | SMITHKLINE BEECHAM CORP (US) | 2008-11-26 | — | — | EP | disclosed |
| EP-1740568-B1 | BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES USEFUL FOR THE TREATMENT OF CARDIOVASCULAR DISEASE. | SMITHKLINE BEECHAM CORP (US) | 2008-11-26 | — | — | EP | disclosed |
| US-20070155805-A1 | Benzofuran and bezothiophene derivatives useful for the treatment of cardiovascular disease | SMITHKLINE BEECHAM CORPORATION | 2007-07-05 | — | — | US | disclosed |
| US-20070155805-A1 | Benzofuran and bezothiophene derivatives useful for the treatment of cardiovascular disease | SMITHKLINE BEECHAM CORPORATION | 2007-07-05 | — | — | US | disclosed |
| US-20070155805-A1 | Benzofuran and bezothiophene derivatives useful for the treatment of cardiovascular disease | SMITHKLINE BEECHAM CORPORATION | 2007-07-05 | — | — | US | disclosed |
| EP-1740568-A2 | BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES USEFUL FOR THE TREATMENT OF CARDIOVASCULAR DISEASE. | SMITHKLINE BEECHAM CORPORATION (US) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005077926-A2 | BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES USEFUL FOR THE TREATMENT OF CARDIOVASCULAR DISEASE | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098480-A1 | ACTIVATING AGENT FOR PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR | PPARA, PPARG, PPARD | MEN1 4646/4885KMT2A 2414/4885DYRK1A 4451/4885 |
| US-20070155805-A1 | Benzofuran and bezothiophene derivatives useful for the treatment of cardiovascular disease | ABAT, BPTF, TNNT2 | MEN1 3656/4885KMT2A 1404/4885DYRK1A 4470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.